Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer (Review)

  • Authors:
    • Emiko Niiro
    • Sachiko Morioka
    • Kana Iwai
    • Yuki Yamada
    • Kenji Ogawa
    • Naoki Kawahara
    • Hiroshi Kobayashi
  • View Affiliations

  • Published online on: January 17, 2018     https://doi.org/10.3892/br.2018.1045
  • Pages:215-223
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Cases of mucinous ovarian cancer are predominantly resistant to chemotherapies. The present review summarizes current knowledge of the therapeutic potential of targeting the Wingless (WNT) pathway, with particular emphasis on preclinical and clinical studies, for improving the chemoresistance and treatment of mucinous ovarian cancer. A review was conducted of English language literature published between January 2000 and October 2017 that concerned potential signaling pathways associated with the chemoresistance of mucinous ovarian cancer. The literature indicated that aberrant activation of growth factor and WNT signaling pathways is specifically observed in mucinous ovarian cancer. An evolutionarily conserved signaling cascade system including epidermal growth factor/RAS/RAF/mitogen‑activated protein kinase kinase/extracellular signal‑regulated protein kinase, phosphoinositide 3‑kinase/Akt and WNT signaling regulates a variety of cellular functions; their crosstalk mutually enhances signaling activity and induces chemoresistance. Novel antagonists, modulators and inhibitors have been developed for targeting the components of the WNT signaling pathway, namely Frizzled, low‑density lipoprotein receptor‑related protein 5/6, Dishevelled, casein kinase 1, AXIN, glycogen synthase kinase 3β and β‑catenin. Targeted inhibition of WNT signaling represents a rational and promising novel approach to overcome chemoresistance, and several WNT inhibitors are being evaluated in preclinical studies. In conclusion, the WNT receptors and their downstream components may serve as novel therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.

Related Articles

Journal Cover

March 2018
Volume 8 Issue 3

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Niiro, E., Morioka, S., Iwai, K., Yamada, Y., Ogawa, K., Kawahara, N., & Kobayashi, H. (2018). Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer (Review). Biomedical Reports, 8, 215-223. https://doi.org/10.3892/br.2018.1045
MLA
Niiro, E., Morioka, S., Iwai, K., Yamada, Y., Ogawa, K., Kawahara, N., Kobayashi, H."Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer (Review)". Biomedical Reports 8.3 (2018): 215-223.
Chicago
Niiro, E., Morioka, S., Iwai, K., Yamada, Y., Ogawa, K., Kawahara, N., Kobayashi, H."Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer (Review)". Biomedical Reports 8, no. 3 (2018): 215-223. https://doi.org/10.3892/br.2018.1045